{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:08:40Z","timestamp":1785420520496,"version":"3.56.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,14]],"date-time":"2016-09-14T00:00:00Z","timestamp":1473811200000},"content-version":"vor","delay-in-days":349,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","derm.theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.det.2015.05.009","type":"journal-article","created":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T17:14:04Z","timestamp":1438449244000},"page":"747-755","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Methotrexate and Pralatrexate"],"prefix":"10.1016","volume":"33","author":[{"given":"Gary S.","family":"Wood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.det.2015.05.009_bib1","first-page":"3493","article-title":"Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate","volume":"6","author":"Krug","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.det.2015.05.009_bib2","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/jid.2008.309","article-title":"Low FAS\/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation","volume":"129","author":"Wu","year":"2009","journal-title":"J\u00a0Invest Dermatol"},{"issue":"3","key":"10.1016\/j.det.2015.05.009_bib3","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1046\/j.0022-202x.2001.01682.x","article-title":"Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and sezary syndrome","volume":"118","author":"Scarisbrick","year":"2002","journal-title":"J\u00a0Invest Dermatol"},{"issue":"2","key":"10.1016\/j.det.2015.05.009_bib4","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1365-2133.2012.10918.x","article-title":"The tumour suppressor p53 is frequently nonfunctional in S\u00e9zary syndrome","volume":"167","author":"Lamprecht","year":"2012","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.det.2015.05.009_bib5","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/jid.2012.10","article-title":"MDM2 inhibitor nutlin-3a induces apoptosis and senescence in cutaneous T-cell lymphoma: role of p53","volume":"132","author":"Manfe","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"issue":"6","key":"10.1016\/j.det.2015.05.009_bib6","doi-asserted-by":"crossref","first-page":"1327.e1","DOI":"10.1016\/j.jaad.2012.05.035","article-title":"The Fas apoptotic pathway in cutaneous T-cell lymphomas: frequent expression of phenotypes associated with resistance to apoptosis","volume":"67","author":"Stutz","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.det.2015.05.009_bib7","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0344-0338(11)80423-1","article-title":"Mycosis fungoides: expression of C-myc p62 p53, bcl-2 and PCNA proteins and absence of association with Epstein-Barr virus","volume":"190","author":"Kanavaros","year":"1994","journal-title":"Pathol Res Pract"},{"issue":"7","key":"10.1016\/j.det.2015.05.009_bib8","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.humpath.2006.10.021","article-title":"Consequences of p16 tumor suppressor gene inactivation in mycosis fungoides and S\u00e9zary syndrome and role of the bmi-1 and ras oncogenes in disease progression","volume":"38","author":"Zhang","year":"2007","journal-title":"Hum Pathol"},{"issue":"11","key":"10.1016\/j.det.2015.05.009_bib9","first-page":"1401","article-title":"Methylation status of the p15, p16 and MGMT promoter genes in primary cutaneous T-cell lymphomas","volume":"89","author":"Gallardo","year":"2004","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.det.2015.05.009_bib10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/labinvest.3780405","article-title":"p16(INK4a) is selectively silenced in the tumoral progression of mycosis fungoides","volume":"82","author":"Navas","year":"2002","journal-title":"Lab Invest"},{"key":"10.1016\/j.det.2015.05.009_bib11","series-title":"Identification and characterization of protein phosphatase 4 regulatory subunit 1 (PP4R1) as a suppressor of NF-kappaB in T lymphocytes and T cell lymphomas","author":"Brechmann","year":"2010"},{"issue":"3","key":"10.1016\/j.det.2015.05.009_bib12","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/sj.cdd.4401157","article-title":"Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation","volume":"10","author":"Hopkins-Donaldson","year":"2003","journal-title":"Cell Death Differ"},{"issue":"21","key":"10.1016\/j.det.2015.05.009_bib13","doi-asserted-by":"crossref","first-page":"5217","DOI":"10.1111\/j.1742-4658.2008.06658.x","article-title":"DNA methylation-mediated nucleosome dynamics and oncogenic Ras signaling: insights from FAS, FAS ligand and RASSF1A","volume":"275","author":"Patra","year":"2008","journal-title":"FEBS J"},{"issue":"4","key":"10.1016\/j.det.2015.05.009_bib14","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1001\/archdermatol.2010.376","article-title":"Reduction of Fas\/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma","volume":"147","author":"Wu","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.05.009_bib15","doi-asserted-by":"crossref","first-page":"e00747","DOI":"10.7554\/eLife.00747","article-title":"Evolutionary dynamics of cancer in response to targeted combination therapy","volume":"2","author":"Bozic","year":"2013","journal-title":"Elife"},{"issue":"18","key":"10.1016\/j.det.2015.05.009_bib16","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2011-11-390211","article-title":"Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"119","author":"Horwitz","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.det.2015.05.009_bib17","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.clml.2012.01.010","article-title":"Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study","volume":"12","author":"Foss","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.det.2015.05.009_bib18","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1365-2141.2007.06658.x","article-title":"Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma","volume":"139","author":"O\u2019Connor","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.det.2015.05.009_bib19","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1200\/JCO.2008.20.8470","article-title":"Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies","volume":"27","author":"O\u2019Connor","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.det.2015.05.009_bib20","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-Cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O\u2019Connor","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.det.2015.05.009_bib21","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jaad.2006.09.011","article-title":"Methotrexate-associated lymphoproliferative disorder in a patient with rheumatoid arthritis presenting in the skin","volume":"56","author":"Clarke","year":"2007","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.05.009_bib22","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.jaad.2005.09.015","article-title":"Reversal of multifocal cutaneous lymphoproliferative disease associated with Epstein-Barr virus after withdrawal of methotrexate therapy for rheumatoid arthritis","volume":"57","author":"Maurani","year":"2007","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.det.2015.05.009_bib23","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1517\/13543780903071038","article-title":"Cladribine: not just another purine analogue?","volume":"18","author":"Spurgeon","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"10.1016\/j.det.2015.05.009_bib24","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S0021-9258(17)31261-9","article-title":"A\u00a0new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis","volume":"264","author":"Beardsley","year":"1989","journal-title":"J\u00a0Biol Chem"},{"issue":"2","key":"10.1016\/j.det.2015.05.009_bib25","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/cbic.201000195","article-title":"Structure and function of mammalian DNA methyltransferases","volume":"12","author":"Jurkowska","year":"2010","journal-title":"Chembiochem"},{"issue":"19\u201320","key":"10.1016\/j.det.2015.05.009_bib26","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1007\/s00018-004-4201-1","article-title":"Biochemistry and biology of mammalian DNA methyltransferases","volume":"61","author":"Hermann","year":"2004","journal-title":"Cell Mol Life Sci"},{"issue":"225","key":"10.1016\/j.det.2015.05.009_bib27","doi-asserted-by":"crossref","first-page":"pe13","DOI":"10.1126\/stke.2252004pe13","article-title":"Methotrexate and Ras methylation: a new trick for an old drug?","volume":"2004","author":"Philips","year":"2004","journal-title":"Sci STKE"},{"issue":"2","key":"10.1016\/j.det.2015.05.009_bib28","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2174\/138945007779940043","article-title":"Targeting the RAS signaling pathway in malignant hematologic diseases","volume":"8","author":"Morgan","year":"2007","journal-title":"Curr Drug Targets"},{"issue":"1","key":"10.1016\/j.det.2015.05.009_bib29","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2119\/molmed.2011.00048","article-title":"Low-dose methotrexate inhibits methionine S-adenosyltransferase in\u00a0vitro and in\u00a0vivo","volume":"18","author":"Wang","year":"2012","journal-title":"Mol Med"},{"key":"10.1016\/j.det.2015.05.009_bib30","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/0190-9622(91)70199-C","article-title":"The pharmacology of methotrexate","volume":"25","author":"Olsen","year":"1991","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2015.05.009_bib31","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/clpt.2009.80","article-title":"A\u00a0population pharmacokinetic and pharmacodynamics evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin\u2019s or Hodgkin\u2019s lymphoma","volume":"86","author":"Mould","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.det.2015.05.009_bib32","series-title":"The pharmacological basis of therapeutics","first-page":"1263","article-title":"Antiproliferative agents and drugs used for immunosuppression","author":"Calabresi","year":"1985"},{"issue":"8","key":"10.1016\/j.det.2015.05.009_bib33","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/jid.2008.16","article-title":"Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis","volume":"128","author":"Warren","year":"2008","journal-title":"J\u00a0Invest Dermatol"},{"issue":"6","key":"10.1016\/j.det.2015.05.009_bib34","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1089\/cbr.2007.0402","article-title":"Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides\/S\u00e9zary syndrome","volume":"22","author":"Aviles","year":"2007","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.det.2015.05.009_bib35","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/0190-9622(93)70069-6","article-title":"Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis","volume":"28","author":"Duhra","year":"1993","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.05.009_bib36","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/j.1365-2133.2006.07289.x","article-title":"Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial","volume":"154","author":"Salim","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2015.05.009_bib37","first-page":"1009","article-title":"Treatment of mycosis fungoides lymphoma: effectiveness of infusions of methotrexate followed by oral citrovorum factor","volume":"62","author":"McDonald","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.det.2015.05.009_bib38","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/1097-0142(196408)17:8<1045::AID-CNCR2820170811>3.0.CO;2-S","article-title":"Observations on the use of cancer chemotherapeutic agents in patients with mycosis fungoides","volume":"17","author":"Wright","year":"1964","journal-title":"Cancer"},{"key":"10.1016\/j.det.2015.05.009_bib39","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0190-9622(96)80062-4","article-title":"Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients","volume":"34","author":"Zackheim","year":"1996","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.05.009_bib40","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0190-9622(03)01591-3","article-title":"Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients","volume":"49","author":"Zackheim","year":"2003","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.05.009_bib41","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1001\/archderm.139.5.624","article-title":"Phase 1\/2 pilot study of methotrexate-laurocapram topical gel for the treatment of patients with early-stage mycosis fungoides","volume":"139","author":"Demierre","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.05.009_bib42","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1001\/archderm.1995.01690150071014","article-title":"Treatment of advanced mycosis fungoides and S\u00e9zary syndrome with continuous infusions of methotrexate followed by fluorouracil and leucovorin rescue","volume":"131","author":"Schappell","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.05.009_bib43","first-page":"750","article-title":"S\u00e9zary syndrome showing a stable clinical course for more than four years after oral administration of etoposide and methotrexate","volume":"41","author":"Hirayama","year":"2000","journal-title":"Rinsho Ketsueki"},{"issue":"15","key":"10.1016\/j.det.2015.05.009_bib44","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2011-05-351346","article-title":"EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma","volume":"118","author":"Kempf","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.det.2015.05.009_bib45","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0190-9622(96)90442-9","article-title":"Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders","volume":"34","author":"Vonderheid","year":"1996","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.05.009_bib46","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0190-9622(03)00470-5","article-title":"Topical methotrexate for lymphomatoid papulosis","volume":"49","author":"Bergstrom","year":"2003","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.05.009_bib47","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1200\/JCO.2002.08.006","article-title":"Trimetrexate in relapsed T-cell lymphoma with skin involvement","volume":"20","author":"Sarris","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.det.2015.05.009_bib48","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1080\/10428190600799961","article-title":"Methotrexate-induced lymphoproliferative disorder in a patient with S\u00e9zary syndrome","volume":"47","author":"Rodrigues","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.det.2015.05.009_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399402004222","article-title":"Aberrant DNA methylation in cancer: potential clinical interventions","volume":"4","author":"Strathdee","year":"2002","journal-title":"Expert Rev Mol Med"},{"key":"10.1016\/j.det.2015.05.009_bib50","doi-asserted-by":"crossref","first-page":"632","DOI":"10.4161\/cc.27523","article-title":"SIRT1 is upregulated in cutaneous T-cell lymphoma and its inhibition induces growth arrest and apoptosis","volume":"I13","author":"Nihal","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1016\/j.det.2015.05.009_bib51","first-page":"S117","article-title":"Epigenetically enhanced photodynamic therapy (ePDT) is superior to conventional PDT for inducing apoptosis in cutaneous T-cell lymphoma (CTCL)","volume":"134","author":"Salva","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"issue":"3","key":"10.1016\/j.det.2015.05.009_bib52","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/jid.2014.364","article-title":"c-CBL E3 ubiquitin ligase is over-expressed in cutaneous T-cell lymphoma: its inhibition promotes activation-induced cell death","volume":"135","author":"Wu","year":"2015","journal-title":"J\u00a0Invest Dermatol"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863515000546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863515000546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T21:01:47Z","timestamp":1652994107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863515000546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0733863515000546"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2015.05.009","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Methotrexate and Pralatrexate","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2015.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}